A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.
9/27/2024
Aachen, Germany, 27 September 2024 – Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO he was Head of Strategy and Portfolio at Grünenthal.
7/22/2024
Aachen, Germany, 22 July 2024 – Grünenthal today announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik® (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Grünenthal will finance the transaction using available liquidity.
7/17/2024
Aachen, Germany, 17 July 2024 – Grünenthal, a leading pharmaceutical company specializing in pain research and management, has announced significant investments in its Latin American production sites. These investments will enhance Grünenthal's production network, ensuring a reliable supply of medicines for patients across Latin America, Europe, and beyond.
Florian Dieckmann
Head Global Corporate Affairs & Communication
Grünenthal GmbH
52099 Aachen
Phone +49 241 569 2555
Fabia Kehren
Head of External Communication and Editorial Management
Grünenthal GmbH
52099 Aachen
Phone +49 241 569-3269
E-Mail Fabia.Kehren@grunenthal.com